biological activity | TDZD-8 (NP 01139) is a non-ATP competitive GSK-3β inhibitor with IC50 of 2 μM; It has minimal inhibitory effect on CDK1, casein kinase II, PKA and PKC. |
target | TargetValue GSK-3β 2 μM |
Target | Value |
GSK-3β
| 2 μM |
in vitro study | TDZD-8 as a non-ATP competitive inhibitor or binding to GS-1. In the kinase experiment, TDZD-8 had no inhibitory effect on PKA, PKC, Cdk-1/cyclin B and CK-II. TDZD-8 specifically induced cell death in primary leukemia cell samples. TDZD-8 can remove leukemia progenitor cells and stem cells. TDZD-8 induces cell death with extremely rapid cell death kinetics and complete cell membrane loss. TDZD-8 acts on primary AML cell samples to inhibit PKC and FLT3. |
in vivo research | TDZD-8 (TDZD8, 1 or 2 mg/kg, I. p.) both reduces the induction of p-DARPP32 following chronic L-dopa treatment in parkinsonian animals. TDZD8 treatment of 21 days induces a significant reduction in PKA expression in rats with established dyskinesia. Moreover, TDZD8 reduces FosB mRNA level in the striatum and expression of PPEB mRNA to similar levels as in 6-OHDA-lesioned rats without treated with L-dopa. The decrease in dyskinesia induced by TDZD8 is overcome by dopamine rceptor-1 agonist. |
use | Glycogen Synthase Kinase-3β is a highly conserved ubiquitously expressed serine/threonine protein kinase involved in signal transduction cascades of multiple cellular processes. TDZD-8 is a thiadiazo lidinone (TDZD) analog that acts as a highly selective, non-ATP competitive inhibitor of GSK-3β ( IC50 = 2nM). binds to the active site of GSK-3β. does not significantly affect the activities of Cd k-1/cyclin B, CK-II, PKA, and PKC (IC50 >100nM). |